Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy

Summary

Evaluating the safety and efficacy of Icotinib administered in 2-month treatments, in patients with metastatic triple-negative breast cancer that have received at least two prior treatments.

Timeline

Start

2015-01

Primary completion

2020-12-15

Completion

2020-12-15

Drugs

Indications